GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XBiotech Inc (NAS:XBIT) » Definitions » 5-Year ROIIC %

XBiotech (XBiotech) 5-Year ROIIC % : 793.75% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is XBiotech 5-Year ROIIC %?

5-Year Return on Invested Incremental Capital (5-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 5-year. XBiotech's 5-Year ROIIC % for the quarter that ended in Dec. 2023 was 793.75%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for XBiotech's 5-Year ROIIC % or its related term are showing as below:

XBIT's 5-Year ROIIC % is ranked better than
93.99% of 1380 companies
in the Biotechnology industry
Industry Median: -19.115 vs XBIT: 793.75

XBiotech 5-Year ROIIC % Historical Data

The historical data trend for XBiotech's 5-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XBiotech 5-Year ROIIC % Chart

XBiotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
5-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.27 22.37 759.53 -8.83 793.75

XBiotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
5-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.83 - - - 793.75

Competitive Comparison of XBiotech's 5-Year ROIIC %

For the Biotechnology subindustry, XBiotech's 5-Year ROIIC %, along with its competitors' market caps and 5-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XBiotech's 5-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XBiotech's 5-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where XBiotech's 5-Year ROIIC % falls into.



XBiotech 5-Year ROIIC % Calculation

XBiotech's 5-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

5-Year ROIIC %=5-Year Incremental Net Operating Profit After Taxes (NOPAT)**/5-Year Incremental Invested Capital**
=( -37.8851 (Dec. 2023) - -20.994 (Dec. 2018) )/( 25.459 (Dec. 2023) - 27.587 (Dec. 2018) )
=-16.8911/-2.128
=793.75%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 5-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


XBiotech  (NAS:XBIT) 5-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


XBiotech 5-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of XBiotech's 5-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


XBiotech (XBiotech) Business Description

Traded in Other Exchanges
Address
5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a United States based clinical-stage biopharmaceutical company. It is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing Anti-IL-1 a therapeutic antibody as a treatment for cancer. Geographically, all of its operations are in the United States.
Executives
Angela Hu officer: Principle Financial Officer 5217 WINNEBAGO LN, AUSTIN TX 78744
John Simard director, 10 percent owner 8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Bay Street Financial S.a. 10 percent owner MEIERHOFSTRASSE 5, LIECHTENSTEIN N2 9490 VADUZ
W Thorpe Mckenzie director, 10 percent owner 735 BROAD ST, STE 1105, CHATTANOOGA TN 37402
Sushma Shivaswamy officer: VP of R&D 8201 E RIVERSIDE DRIVE, BLDG 4, STE 100, AUSTIN TX 78744
Queena Han officer: VP of Fin & HR, Secretary 8201 E RIVERSIDE DRIVE, BLDG 4 STE 100, AUSTIN TX 78744
Thomas Gut 10 percent owner CO LINDENBERG FAMILY OFFICE LTD, LATERNENGASSE 5, ZURICH V8 8001
Peter Libby director 109 LARCH ROAD, CAMBRIDGE MA 02138
Fondation Rennes 10 percent owner RATIKONSTRASSE 13, VADUZ, PRINCIPALITY OF LIECHTENSTEIN N2 FL-9490
Donald H. Macadam director 56 KELLY DRIVE, PORT DOVER A6 N0A 1N5
Jan-paul Waldin director 77 KING STREET WEST, SUITE 3000, TORONTO A6 M5K 1G8
Benjamin Guzman officer: Sr.VP Corp. Strategy & Finance 8201 E RIVERSIDE DR BLDG. 4 STE 100, AUSTIN TX 78744
Trey Benson officer: VP of Commercial Development 8201 E. RIVERSIDE DR., BUILDING 4, SUITE 100, AUSTIN TX 78744
Kalidip Choudhury officer: VP of Business Development 8201 E. RIVERSIDE DRIVE, BUILDING 4, SUITE 100, AUSTIN TX 78744
Dawn Mccollough officer: VP Clinical Operations 115 SANDRA MURAIDA WAY, #838, AUSTIN TX 78703